Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427614 | 0.81 | CDK1 (0.47) | XDHTK1KMT2ACDK1CYP3A4 | |
| SCHEMBL21362203 | 0.81 | XDH (0.41) | XDHTK1KMT2ACYP3A4ADORA3 | |
| 9-Methylguanine SCHEMBL22884 | 0.81 | XDH (0.58) | XDHTK1KMT2AHPRT1PNP | |
| SCHEMBL18521149 | 0.81 | CDK1 (0.40) | XDHTK1KMT2ACDK1CYP3A4 | |
| SCHEMBL12702573 | 0.78 | PI4KA (0.41) | XDHTK1KMT2AADORA3PNP | |
| SCHEMBL20655295 | 0.78 | XDH (0.40) | XDHTK1KMT2AADORA3HPRT1 | |
| SCHEMBL754057 | 0.78 | CDK2 (0.47) | XDHKMT2ACDK1HPRT1 | |
| SCHEMBL25100647 | 0.78 | CDK1 (0.38) | XDHTK1CDK1CYP3A4MAPK1 | |
| SCHEMBL10037062 | 0.78 | YTHDC1 (0.46) | TK1KMT2ACDK1CYP3A4MAPK1 | |
| SCHEMBL17898192 | 0.78 | CDK1 (0.38) | XDHTK1CDK1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| EP-3765474-B1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2019175776-A1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20180065965-A1 | SULFAMIDE AND SULFAMATE INHIBITORS OF hHint1 | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-08 | — | — | US | disclosed |
| US-20170369876-A1 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9708357-B2 | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | Riboscience, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9700560-B2 | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9487772-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| US-8193165-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-8076461-B2 | antibody microarray for detecting incomplete deprotection of synthetic test oligonucleotides; high throughput assay; solid phase synthesis | PROTEOME SCIENCES PLC (GB) | 2011-12-13 | — | — | US | disclosed |
| US-20110092574-A1 | mRNA Cap Analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-25 | — | — | US | disclosed |
| US-7589078-B2 | Using a dideoxy and didehydro nucleoside | YALE UNIVERSITY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | XDH 1435/4885TK1 216/4885KMT2A 2385/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | XDH 4334/4885TK1 536/4885KMT2A 3249/4885 |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | XDH 4334/4885TK1 536/4885KMT2A 3249/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | XDH 4334/4885TK1 536/4885KMT2A 3249/4885 |
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | TYMP, ITPA, SAMHD1 | XDH 169/4885TK1 91/4885KMT2A 1891/4885 |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | XDH 4334/4885TK1 536/4885KMT2A 3249/4885 |
| US-20170369876-A1 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | RBM17, MBNL1, UTRN | XDH 4765/4885TK1 2630/4885KMT2A 3575/4885 |
| US-20180065965-A1 | SULFAMIDE AND SULFAMATE INHIBITORS OF hHint1 | GRIN1, GRIA1, GRIN2A | XDH 1609/4885TK1 2245/4885KMT2A 367/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | XDH 1174/4885TK1 98/4885KMT2A 1334/4885 |
| US-20110092574-A1 | mRNA Cap Analogs | RNMT, RNGTT, NSUN2 | XDH 4634/4885TK1 2356/4885KMT2A 2408/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | XDH 2529/4885TK1 1827/4885KMT2A 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.